New York, NY -- (SBWIRE) -- 01/10/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Tower Group International, Ltd (NASDAQ:TWGP), Dynavax Technologies Corporation (NASDAQ:DVAX), Opko Health Inc (NYSE:OPK), Antares Pharma Inc (NASDAQ:ATRS)
Tower Group International, Ltd (NASDAQ:TWGP) showed a volume of 3.02 million shares by the end of last trade whereas the average volume of the stock remained 3.63million shares. The stock opened the session at $2.92 but then moved to $2.73. At that price, the stock showed a negative performance of -4.88%.
Will TWGP Get Buyers Even After The Recent Rally? Find Out Here
Dynavax Technologies Corporation (NASDAQ:DVAX) opened the session at $1.91 and closed the session at $1.94. The stock showed a positive performance of 2.11% in previous trading session. Traded with volume of 2.98 million shares in the prior session and the average volume of the stock remained 5.07 million shares. Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines. The Company’s pipeline of product candidates includes HEPLISAV,
For How Long DVAX will fight for Profitability? Read This Trend Analysis report
Opko Health Inc (NYSE:OPK) opened the session at $8.46 and closed the session at $8.43. The stock showed a negative performance of -0.59% in previous trading session. The beta of the stock remained 1.00. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions.
Why Should Investors Buy OPK After the Recent Fall? Just Go Here and Find Out
Antares Pharma Inc (NASDAQ:ATRS) the stock advanced 1.67% and finished the session at $4.88. Traded with volume of 2.93 million shares in the prior session and the average volume of the stock remained 1.24 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.
Will ATRS Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)